Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $76 (market cap $2.00B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.5× Global X Robo Global Robotics & Automation ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 38 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ROBO | TVTX | |
|---|---|---|
Market Cap | $2.00B | $5.02B |
Volume | 99,806 | 2,060,842 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $67.52 |
52-Week Low | $63.04 | $26.79 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.85, down 0.22% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The robotics ETF faces mixed sentiment amid AI-driven sector growth but lacks current fundamental data for valuation metrics. Recent news highlights robotics adoption expanding beyond automotive into manufacturing, healthcare, and military applications, though earnings visibility remains limited for underlying holdings.
The outlook for ROBO hinges on broader AI and robotics adoption trends, with potential from labor shortages and military demand, but risks include valuation concerns in tech and cyclical exposure. Investors should monitor earnings from constituent companies for fundamental validation of growth narratives amid neutral oscillator signals and bearish technical momentum.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
